Traders sold shares of Shire PLC (NASDAQ:SHPG) on strength during trading on Friday. $18.77 million flowed into the stock on the tick-up and $43.82 million flowed out of the stock on the tick-down, for a money net flow of $25.05 million out of the stock. Of all stocks tracked, Shire PLC had the 0th highest net out-flow for the day. Shire PLC traded up $0.29 for the day and closed at $140.36
A number of analysts recently weighed in on the company. Cantor Fitzgerald restated a “buy” rating and issued a $222.00 price target on shares of Shire PLC in a research note on Thursday, September 14th. BidaskClub downgraded Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Jefferies Group LLC restated a “hold” rating and issued a $206.00 price target (down from $216.00) on shares of Shire PLC in a research note on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. Shire PLC has a consensus rating of “Hold” and a consensus price target of $211.00.
The stock has a market capitalization of $42,151.51, a price-to-earnings ratio of 9.65, a price-to-earnings-growth ratio of 0.78 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.64 by $0.17. The company had revenue of $3.70 billion during the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business’s revenue was up 7.1% compared to the same quarter last year. During the same period last year, the firm earned $3.17 earnings per share. equities research analysts predict that Shire PLC will post 15 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the company. Hartford Financial Management Inc. grew its position in shares of Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares during the period. YorkBridge Wealth Partners LLC grew its position in Shire PLC by 81.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 317 shares during the period. Pacer Advisors Inc. purchased a new stake in Shire PLC during the second quarter valued at about $171,000. Stephens Inc. AR grew its position in Shire PLC by 22.2% during the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 228 shares during the period. Finally, Ingalls & Snyder LLC grew its position in Shire PLC by 10.8% during the second quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 125 shares during the period. 19.24% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Investors Sell Shares of Shire PLC (SHPG) on Strength (SHPG)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/12/investors-sell-shares-of-shire-plc-shpg-on-strength-shpg.html.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.